Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for gleason score 7 prostate cancer

Cancer

Volumn 110, Issue 2, 2007, Pages 289-296

  Merrick, Gregory S ^a   Galbreath, Robert W ^a,b   Butler, Wayne M ^a   Waller, Kent E ^c   Allen, Zachariah A ^a   Lief, Jonathan ^a   Adamovich, Edward ^d  

^a WHEELING HOSPITAL   (United States)

^b Ohio University Eastern   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

^d WHEELING JESUIT UNIVERSITY   (United States)

Author keywords

Brachytherapy; Cause specific survival; Gleason score 7; Overall survival; Prostate cancer

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; IODINE 125; PALLADIUM; PALLADIUM 103; PALLADIUM 36; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COMPUTER ASSISTED RADIOTHERAPY; DIABETES MELLITUS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; LINEAR REGRESSION ANALYSIS; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PARAMETER; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; SMOKING; SURVIVAL RATE;

AGED; BRACHYTHERAPY; COHORT STUDIES; DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 34547188801     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22793     Document Type: Article

References (30)

1. Herman CM, Kattan MW, Ohori M, et al. Primary Gleason pattern as a predictor of disease progression in Gleason score 7 prostate cancer. Am J Surg Pathol. 2001;25:657-660.
2. Lerner SE, Blute ML, Bergstralh EJ, et al. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. Urol. 1996;156:137-143.
3. Roehl KA, Han M, Ramos CG, et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. Urology. 2004;172:910-914.
4. Chan TY, Partin AW, Walsh PC, et al. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology. 2000;56:823-827.
5. Sakr WA, Tefilli MV, Grignon DJ, et al. Gleason score 7 prostate cancer: a heterogenous entity? Correlation with pathologic parameters and disease-free survival. Urology. 2000;56:730-734.
6. D'Amico AV, Renshaw AA, Schultz D, et al. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA ≤ 10 ng/mL and T1c,2a: implications for patient selection for prostate-only therapy. Int J Radiat Oncol Biol Phys. 1999;45:847-851.
7. Merrick GM, Butler WM, Wallner KE, et al. The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naïve Gleason score 7 prostate cancer. Cancer J. 2005;11:234-240.
8. Tollefson MK, Leibovich BC, Slezak JM, et al. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol. 2006;175:547-551.
9. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update or prostate cancer staging nomograms (Partin tables) for the new millennium. Urology. 2001;58:843-848.
10. Tefilli MV, Gheiler EL, Tiguert R, et al. Should Gleason score 7 prostate cancer be considered a unique grade category?. Urology. 1999;53:372-377.
11. Groll R, Fleshner NE, Sugar L, et al. Clinical significance of biopsy-derived primary Gleason score among radical prostatectomy candidates with Gleason 7 tumors. Urology. 2002;59:551-554.
12. Vira M, Tomaszewski J, Hwang W, et al. Impact of the percentage of positive biopsy cores on the further stratification of primary grade 3 and grade 4 Gleason score 7 tumors in radical prostatectomy patients. Urology. 2005;66:1015-1019.
13. Potters L, Purrazzella R, Brustein S, et al. The prognostic significance of Gleason grade in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;56:749-754.
14. Anderson PR, Hanlon AL, Horwitz E, et al. Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treatment with three-dimensional conformal external beam radiation therapy. Cancer. 2000;89:2565-2569.
15. Merrick GS, Butler WM, Wallner KE, et al. Modified uniform seed loading for prostate brachytherapy: rationale, design and evaluation. Tech Urol. 2000;6:78-84.
16. Merrick GS, Butler WM, Wallner KE, et al. Extracapsular radiation dose distribution following permanent prostate brachytherapy. Am J Clin Oncol. 2003;26:E178-E189.
17. Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: recommendations for the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 1995;22:209-234.
18. Merrick GS, Wallner KE, Butler WM. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol. 2003;169:1643-1652.
19. Merrick GS, Butler WM, Wallner KE, et al. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Urology. 2005;65:95-100.
20. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006;296:2329-2335.
21. Do TM, Parker RG, Smith RB, et al. High-grade carcinoma of the prostate: a comparison of current local therapies. Urology. 2001;57:1121-1127.
22. Valicenti R, Lu J, Pilepich M, et al. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated in the Radiation Therapy Oncology Group trials. J Clin Oncol. 2000;18:2740-2746.
23. Martinez AA, Gustafson G, Gonazales J, et al. Dose escalation using conformal high-dose rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:316-327.
24. 3 predicts for a favorable outcome after radical prostatectomy for localized prostate cancer. Urology. 1998;52:631-636.
25. Fitzsimmons N, Presti J, Kane C, et al. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathologic Gleason score?. J Urol. 2006;176:2453-2458.
26. Wallner KE, Merrick GM, True L, et al. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial. Radiother Oncol. 2005;75:307-310.
27. Merrick GM, Butler WM, Wallner KE, et al. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;65:669-677.
28. Beyer DC, McKeough T, Thomas T, et al. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;61:1299-1305.
29. Moyad MA. Step-by-step lifestyle changes that can improve urologic health in men. Part I. What do I tell my patients? Prim Care Clin Office Pract. 2006;33:139-163.
30. Moyad MA. Step-by-step lifestyle changes that can improve urologic health in men. Part II. What do I tell my patients? Prim Care Clin Office Pract. 2006;33:165-185.